Ocumetics lens technology provides 12 diopters of accommodation in bench testing

(via TheNewswire)

Calgary, AB–TheNewswire –May 24, 2022 – Ocumetics Technology Corp. (“Ocumetics“or the”Company”) (TSXV:OTC) is pleased to provide an update on the results of preclinical bench testing of its lens technologies.

In recent bench tests conducted by Accommodation-in-Bench-Tests-40528338/xmltag.org”>Ocumeticsthe company’s latest accommodating lens design consistently achieves 12 diopters of accommodation, allowing the eye to focus on objects within 4 inches.

“These remarkable results are the culmination of more than 15 years of research by our founder and Chief Scientific Officer, Dr. Garth Webb,” said Dr. Mark LeeCEO of Ocumetics. “While lab results need to be verified in clinical trials, I believe our products have the potential to be transformative in the eye care industry,” adds Dr. Lee.

“The lens was designed to produce 12 diopters of accommodation, and it’s gratifying to see the prototypes deliver these results in bench testing,” said Dr. Garth Webb, the lens technologies from inventor Ocumetics. “Also, the clarity of the images produced by the lens itself is everything we hoped for,” adds Dr Webb.

“If Ocumetics’ lens technologies can only achieve half the bench test accommodation amplitude in human trials, we will be able to offer older adults the opportunity to have near vision as they had when they were teenagers.“, said Dr. Doyle StultingChief Medical Officer of Ocumetics.

Preclinical studies for Ocumetics’ accommodating lens technology are expected to be completed in Q3 2022. First-in-human proof-of-concept studies are expected to begin shortly thereafter, in Q4 2022. Full clinical trials are expected to begin in 2023.

On Ocumetics

Ocumetics Technology Corp.(TSXV: “OTC” is a Canadian research and product development company specializing in the design of adaptive lenses. Ocumetics is in the preclinical stage of a breakthrough technology for the ophthalmic industry. Ocumetics has developed an expandable intraocular lens that fits into the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses. It is designed to allow the eye’s natural muscle activity to shift from distance to nearness.

FOR MORE INFORMATION, PLEASE CONTACT:

dr. Mark Lee

President and CEO

(604) 832-6052

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTION REGARDING FORWARD-LOOKING INFORMATION: This press release contains certain “forward-looking statements” under applicable Canadian securities laws. avant-gardestatements include, but are not limited to, statements regarding the commencement, timing and scope of the clinical trial program described above and that it will be conducted as planned. Forward-looking statements are necessarily based on a number of estimates and assumptions which, while believed to be reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results to differ. and future events differ materially from those expressed or implied. by such forward-looking statements. These factors include, but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing and other considerations deemed appropriate in the circumstances. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Copyright (c) 2022 TheNewswire – All Rights Reserved.

Copyright (c) 2022 TheNewswire – All rights reserved., source Press Releases